New therapies in celiac disease: 2026 pipeline
Decision brief
Answer first · skim in under a minute
New therapies in celiac disease are advancing as the field moves beyond diet-only management. Current evidence also highlights updated diagnostic thinking and a shift toward drugs in advanced clinical phases.
New therapies in celiac disease are moving from diet-only management into Phase 2 programs that target gluten tolerance, tissue transglutaminase 2, and inflammatory cytokines. No FDA-approved pharmacotherapy exists yet. Reviews and trial registries show advanced-phase candidates with defined mechanisms, while adult diagnosis still centers on duodenal biopsy.
Contents10 sections
Key Takeaways
- A gluten-free diet remains the only proven standard; no FDA-approved drug for celiac disease is available as of mid-2026.
- A 2024 PMC review frames the pipeline around drugs in advanced clinical phases that hit specific signaling pathways, not mechanism-agnostic early concepts.
- TAK-101 Phase 2a data showed an 88% reduction in gluten-induced interferon-gamma responses versus placebo (2.01 vs 17.58 spot-forming units; P = .006).
- Registry activity in 2025–2026 includes completed TAK-101 dose-ranging (NCT04530123; 102 participants) and Sanofi amlitelimab Phase 2a/b (NCT06557772; 229 participants).
Why are new therapies in celiac disease needed now?
Celiac disease affects roughly 1% of the global population. Strict gluten-free diet adherence is incomplete for many patients, and up to 30% report persistent symptoms despite diet. Reviews estimate that about 30%–60% of adults do not achieve histological recovery after one year on a strict diet. Those gaps drive demand for adjunct pharmacotherapy.
Primary literature also notes average gluten contamination around 150 mg/day in supposedly adherent patients, far above amounts considered safe in challenge studies. That real-world exposure explains why sponsors design gluten-challenge Phase 2 trials rather than diet-only endpoints alone.
What does the evidence say about pipeline mechanisms?
A World Journal of Gastroenterology review on PMC11525874 groups candidates into quantitative strategies (enzymatic gluten degradation, sequestration, permeability modulators) and qualitative strategies (immunomodulation and gluten tolerance). The authors emphasize drugs already in advanced clinical phases that target defined pathways such as tissue transglutaminase 2 and lymphocyte trafficking.
That framing matters for BD teams: the competitive set is mechanism-specific Phase 2 assets, not a single late-stage winner. Larazotide’s earlier Phase 3 failure is a cautionary data point outside this article’s primary citations and is not treated here as an active late-stage bet.
TAK-101 gluten-tolerance data and registry status
TAK-101 encapsulates gliadin in negatively charged PLGA nanoparticles to induce antigen-specific tolerance. In a randomized Phase 2a gluten-challenge study summarized in Gastroenterology literature and linked trial records, TAK-101 cut the rise in circulating gliadin-specific interferon-gamma–producing cells by 88% versus placebo.
- Phase 2a interferon-gamma spot-forming units: 2.01 (TAK-101) vs 17.58 (placebo); P = .006
- Villus height to crypt depth ratio worsened on placebo (−0.63; P = .002) but not significantly on TAK-101 (−0.18; P = .110); intergroup P = .08
- Dose-ranging registry NCT04530123: Phase 2, 102 participants, primary completion Dec. 9, 2025, study completed Jan. 8, 2026
Those numbers support immune-activation claims. They do not yet prove approval-ready histological superiority or symptom control in larger Phase 3 populations.
Which other Phase 2 programs are active in 2025–2026?
Sanofi’s amlitelimab program in nonresponsive celiac disease (NCT06557772) is a Phase 2a/b, six-arm, placebo-controlled study enrolling 229 adults. The primary mucosal endpoint is change in villous height to crypt depth ratio with and without simulated inadvertent gluten exposure. Primary completion is estimated Aug. 5, 2026.
Additional registry entries from 2025 postings include Teva TEV-53408 (NCT06807463; 50 participants), Forte FB102 (NCT06982963; about 100 participants), Chugai DONQ52 (NCT07239336), and Falk/Zedira ZED1227 (NCT07298343; about 356 participants). Most use gluten challenge plus histology or symptom scores. None of these registry pages report FDA approval.
How should adult diagnosis shape trial enrollment?
Adult diagnosis still relies on endoscopy with duodenal biopsy as the gold standard in practice guidelines and advocacy summaries. Non-biopsy approaches are discussed mainly for patients with extremely high tissue transglutaminase antibody titers, not as a universal replacement. Trial protocols that require biopsy-confirmed disease therefore remain aligned with clinical reality for adults.
For sponsors, that constraint affects screening cost and screen-fail rates. For payers and clinicians, it means pharmacotherapy candidates will be judged against histology and patient-reported outcomes on top of diet, not instead of diagnostic rigor.
What remains unproven for new therapies in celiac disease
No cited primary source confirms an FDA-approved celiac drug, a labeled indication, or a commercial price. TAK-101’s Phase 2a immune endpoint is strong, but the villous height to crypt depth intergroup difference was not statistically significant (P = .08). Larger Phase 2b/3 readouts for amlitelimab, ZED1227, and peer programs are still pending through 2026–2027 per registry estimates. Claims about cure rates, diet discontinuation, or market size are not supported by the sources used here and are omitted.
Related NovaPharma coverage
- Adial Pharmaceuticals Azora merger and ulcerative colitis pipeline
- Takeda TYK2 psoriasis head-to-head data
- Sanofi pipeline catalysts for 2026
Frequently Asked Questions
Are there FDA-approved new therapies in celiac disease?
No. As of mid-2026, a lifelong gluten-free diet remains the only standard treatment. Multiple Phase 2 programs are testing pharmacologic options, but none are FDA-approved for celiac disease.
What is TAK-101 and what did Phase 2a show?
TAK-101 is a gliadin-encapsulated nanoparticle designed to induce gluten-specific tolerance. In a Phase 2a gluten-challenge study, it reduced interferon-gamma spot-forming units by 88% versus placebo (2.01 vs 17.58; P = .006).
Which late-stage trial pathways are active in 2026?
Active or completed Phase 2 registries include Takeda TAK-101 (NCT04530123; completed Jan. 8, 2026), Sanofi amlitelimab in nonresponsive celiac disease (NCT06557772; 229 participants), and other gluten-challenge programs measuring villous height to crypt depth ratios.
Primary Sources
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
